3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
11
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
6
Lung Neoplasms
4
Colorectal Neoplasms
3
Neoplasm Metastasis
2
Melanoma
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
1
Mesothelioma, Malignant
1
Mesothelioma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Interventions
pembrolizumab
42
Carboplatin
24
Cyclophosphamide
20
Paclitaxel
19
Nivolumab
17
Cisplatin
15
fludarabine
14
Gemcitabine
12
aldesleukin
10
Docetaxel
10
Bevacizumab
9
Magnetic Resonance Spectroscopy
8
Trastuzumab
7
Specimen Handling
7
Drug Therapy
7
Pemetrexed
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Fluorouracil
6
Cetuximab
6
Blood Specimen Collection
6
sargramostim
5
pegfilgrastim
5
avelumab
5
Topotecan
5
Taxes
5
Irinotecan
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
dostarlimab
×
Thoracic
×
Clear all
NCT03250832
2024-04-11
CITRINO
Tesaro, Inc.
Phase 1
Completed
111 enrolled
48 charts